Critical Care

, 14:432 | Cite as

Assessment of monocytic HLA-DR expression in ICU patients: analytical issues for multicentric flow cytometry studies

  • Guillaume Monneret
  • Fabienne Venet
  • Christian Meisel
  • Joerg C Schefold


Septic Patient Standardize Environment Analytical Requirement Future Care Consecutive Measurement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



intensive care unit


monocytic human leukocyte antigen DR-1.

We read with interest the recent report by Gogos and colleagues [1]. While the rationale for their study is excellent, we would like to comment on technical issues that may have influenced the results.

As stated, a time limit of 8 hours between sample drawing and staining at a central laboratory was specified [1]. Unfortunately, information regarding transport conditions is missing (average time, temperature). This seems important since monocytic HLA-DR expression (mHLA-DR) increases artificially over time [2, 3]. Consequently, recommendations suggest that sample staining for mHLA-DR should occur within 4 hours [2, 3]. Although the authors aimed to address the effect of transportation, they inappropriately used samples presenting with already near-maximal mHLA-DR values (> 90%) before storage. We therefore assume that mHLA-DR results may be falsely elevated due to prolonged transportation times. Furthermore, mHLA-DR modulation during sepsis takes days and consecutive measurements are required [4]. Assessment of one early sample (within the first 24 hours) is probably inappropriate to investigate the impact of infection on mHLA-DR. Similarly, apoptosis staining should not be performed after 8 hours and experts' recommendations highlight the need for dedicated protocols on fresh cells [5].

We are convinced that successful future trials in sepsis will rely on our capacity to accurately assess immune responses. In that sense, flow cytometry multicentric clinical studies are essential. Such trials should be performed in standardized environments in accordance with specific (pre)analytical requirements. Otherwise, results might be misinterpreted and may impede promising new avenues in future care of septic patients.



  1. 1.
    Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa P, Adamis S, Alexiou Z, Andrianopoulos G, Antonopoulou A, Athanassia S, Baziaka F, Charalambous A, Christodoulou S, Dimopoulou I, Floros I, Giannitsioti E, Gkanas P, Ioakeimidou A, Kanellakopoulou K, Karabela N, Karagianni V, Katsarolis I, Kontopithari G, Kopterides P, Koutelidakis I, Koutoukas P, Kranidioti H, Lignos M, Louis K, et al.: Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 2010, 14: R96. 10.1186/cc9031PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Monneret G, Elmenkouri N, Bohe J, Debard AL, Gutowski MC, Bienvenu J, Lepape A: Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. Clin Chem 2002, 48: 1589-1592.PubMedGoogle Scholar
  3. 3.
    Döcke WD, Höflich C, Davis KA, Röttgers K, Meisel C, Kiefer P, Weber SU, Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, Nebe T, Engel A, Monneret G, Spittler A, Schmolke K, Reinke P, Volk HD, Kunz D: Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005, 51: 2341-2347. 10.1373/clinchem.2005.052639CrossRefPubMedGoogle Scholar
  4. 4.
    Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P: Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32: 1175-1183. 10.1007/s00134-006-0204-8CrossRefPubMedGoogle Scholar
  5. 5.
    Ayala A, Perl M, Venet F, Lomas-Neira J, Swan R, Chung CS: Apoptosis in sepsis: mechanisms, clinical impact and potential therapeutic targets. Curr Pharm Des 2008, 14: 1853-1859. 10.2174/138161208784980617CrossRefPubMedGoogle Scholar

Copyright information

© BioMed Central Ltd 2010

Authors and Affiliations

  • Guillaume Monneret
    • 1
  • Fabienne Venet
    • 1
  • Christian Meisel
    • 2
  • Joerg C Schefold
    • 3
  1. 1.Cellular Immunology Laboratory, Hôpital E. HerriotHospices Civils de LyonLyon Cedex 03France
  2. 2.Department of Medical ImmunologyCharité University MedicineBerlinGermany
  3. 3.Charite University MedicineDepartment of Nephrology and Intensive Care MedicineBerlinGermany

Personalised recommendations